Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
Tóm tắt
Từ khóa
Tài liệu tham khảo
Licitra, 2016, Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck, Oral Oncol, 52, 18, 10.1016/j.oraloncology.2015.10.020
Sobecki-Ryniak, 2013, Head and neck cancer: historical evolution of treatment and patient self-care requirements, Clin J Oncol Nurs, 17, 659, 10.1188/13.CJON.659-663
Rhoten, 2013, Body image in patients with head and neck cancer: a review of the literature, Oral Oncol, 49, 753, 10.1016/j.oraloncology.2013.04.005
Singer, 2012, Predictors of emotional distress in patients with head and neck cancer, Head Neck, 34, 180, 10.1002/hed.21702
Saloura, 2014, An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck, Cancer Chemother Pharmacol, 73, 1227, 10.1007/s00280-014-2459-z
Urba, 2012, Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study, Cancer, 118, 4694, 10.1002/cncr.27449
Mesia, 2010, Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck, Ann Oncol, 21, 1967, 10.1093/annonc/mdq077
Machiels, 2015, Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial, Lancet Oncol, 16, 583, 10.1016/S1470-2045(15)70124-5
Murphy, 2013, To treat or not to treat: balancing therapeutic outcomes, toxicity and quality of life in patients with recurrent and/or metastatic head and neck cancer, J Support Oncol, 11, 149, 10.12788/j.suponc.0005
Urba, 2012, Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy, Oral Oncol, 48, 723, 10.1016/j.oraloncology.2012.02.016
Homet Moreno, 2015, Anti-programmed cell death protein-1/ligand-1 therapy in different cancers, Br J Cancer, 112, 1421, 10.1038/bjc.2015.124
Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643
Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627
Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1803, 10.1056/NEJMoa1510665
Ferris, 2016, Nivolumab for recurrent squamous-cell carcinoma of the head and neck, N Engl J Med, 375, 1856, 10.1056/NEJMoa1602252
Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026
Bjordal, 2000, A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group, Eur J Cancer, 36, 1796, 10.1016/S0959-8049(00)00186-6
Bottomley, 2014, An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group, Cancer, 120, 390, 10.1002/cncr.28392
Curran, 2007, Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab, J Clin Oncol, 25, 2191, 10.1200/JCO.2006.08.8005
Sherman, 2000, Assessing quality of life in patients with head and neck cancer: cross-validation of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Head and Neck module (QLQ-H&N35), Arch Otolaryngol Head Neck Surg, 126, 459, 10.1001/archotol.126.4.459
Pickard, 2007, Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer, Health Qual Life Outcomes, 5, 70, 10.1186/1477-7525-5-70
Aaronson, 1993, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 85, 365, 10.1093/jnci/85.5.365
Fayers, 2002, Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer, Eur J Cancer, 38, S125, 10.1016/S0959-8049(01)00448-8
Fayers, 2001
Bjordal, 1994, Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients. EORTC Quality of Life Study Group, Acta Oncol, 33, 879, 10.3109/02841869409098450
Bjordal, 1999, Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35, J Clin Oncol, 17, 1008, 10.1200/JCO.1999.17.3.1008
1990, EuroQol—a new facility for the measurement of health-related quality of life, Health Policy, 16, 199, 10.1016/0168-8510(90)90421-9
Dolan, 1997, Modeling valuations for EuroQol health states, Med Care, 35, 1095, 10.1097/00005650-199711000-00002
Osoba, 1998, Interpreting the significance of changes in health-related quality-of-life scores, J Clin Oncol, 16, 139, 10.1200/JCO.1998.16.1.139
Cocks, 2012, Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30, Eur J Cancer, 48, 1713, 10.1016/j.ejca.2012.02.059
Cocks, 2011, Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30, J Clin Oncol, 29, 89, 10.1200/JCO.2010.28.0107
Anota, 2015, Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?, Qual Life Res, 24, 5, 10.1007/s11136-013-0583-6
Long, 2016, Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study, Ann Oncol, 27, 1940, 10.1093/annonc/mdw265
Reck, 2015, Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017, Eur J Cancer, 51, S599, 10.1016/S0959-8049(16)31656-2
Reck, 2016, Overall health status in patients with advanced non-squamous NSCLC treated with nivolumab or docetaxel in CheckMate 057, Ann Oncol, 27, 1217PD, 10.1093/annonc/mdw594.006
Cella, 2016, Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial, Lancet Oncol, 17, 994, 10.1016/S1470-2045(16)30125-5
Tschiesner, 2013, Priorities of head and neck cancer patients: a patient survey based on the brief ICF core set for HNC, Eur Arch Otorhinolaryngol, 270, 3133, 10.1007/s00405-013-2446-8
Metcalfe, 2014, What patients consider important: temporal variations by early and late stage oral, oropharyngeal and laryngeal subsites, J Craniomaxillofac Surg, 42, 641, 10.1016/j.jcms.2013.09.008
van Herpen, 2010, Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323), Br J Cancer, 103, 1173, 10.1038/sj.bjc.6605860
Ojo, 2012, A systematic review of head and neck cancer quality of life assessment instruments, Oral Oncol, 48, 923, 10.1016/j.oraloncology.2012.03.025